Now PlayingEP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
Shaping the Future of Community Bispecific Administration: Lessons From ASH 2025ByTara Graff, DO January 29th 2026
Sequencing, Real-World Evidence, and Unmet Needs: Key Immunotherapy Insights From ASH 2025 in Multiple MyelomaByKrina Patel, MD, MScJanuary 29th 2026
The Promise of In Vivo CAR T: Expanding Access Through Off-the-Shelf InnovationByKrina Patel, MD, MScJanuary 29th 2026
Optimizing Adverse Event Management for Bispecific Antibodies in the CommunityByTara Graff, DO January 29th 2026
Safety Considerations and Patient-Reported Outcomes of TKIs in HER2-Mutant NSCLCByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhDJanuary 28th 2026